These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 21876406)

  • 21. [External exposure of hot cell operators in nuclear medicine].
    Sichirollo AE; Bombardieri E; Cortona G; Marchesini R
    Radiol Med; 1998 Dec; 96(6):612-7. PubMed ID: 10189927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extremity dosimetry for radiation workers handling unsealed radionuclides in nuclear medicine departments in India.
    Tandon P; Venkatesh M; Bhatt BC
    Health Phys; 2007 Feb; 92(2):112-8. PubMed ID: 17220712
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blood clearance and occupational exposure for
    Abuqbeitah M; Demir M; Uslu-Beşli L; Yeyin N; Sönmezoğlu K
    Radiat Environ Biophys; 2018 Mar; 57(1):55-61. PubMed ID: 29149420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiation protection in radionuclide therapies with (90)Y-conjugates: risks and safety.
    Cremonesi M; Ferrari M; Paganelli G; Rossi A; Chinol M; Bartolomei M; Prisco G; Tosi G
    Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1321-7. PubMed ID: 16832636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose rates in nuclear medicine and the effectiveness of lead aprons: updating the department's knowledge on old and new procedures.
    Young AM
    Nucl Med Commun; 2013 Mar; 34(3):254-64. PubMed ID: 23353888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model.
    Madsen MT; Bushnell DL; Juweid ME; Menda Y; O'Dorisio MS; O'Dorisio T; Besse IM
    J Nucl Med; 2006 Apr; 47(4):660-7. PubMed ID: 16595501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [beta-Radiation exposure with (188)Re-labelled pharmaceuticals].
    Andreeff M; Wunderlich G; Behge K; Schönmuth T; Kotzerke J
    Nuklearmedizin; 2005; 44(3):94-8. PubMed ID: 15968417
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Occupational exposure doses in interventional procedures in Bosnia and Herzegovina.
    Bašić B; Beganović A; Skopljak-Beganović A; Samek D
    Radiat Prot Dosimetry; 2011 Mar; 144(1-4):501-4. PubMed ID: 21138927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN).
    Wild D; Frischknecht M; Zhang H; Morgenstern A; Bruchertseifer F; Boisclair J; Provencher-Bolliger A; Reubi JC; Maecke HR
    Cancer Res; 2011 Feb; 71(3):1009-18. PubMed ID: 21245097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumoral fibrosis effect on the radiation absorbed dose of (177)Lu-Tyr(3)-octreotate and (177)Lu-Tyr(3)-octreotate conjugated to gold nanoparticles.
    Azorín-Vega EP; Zambrano-Ramírez OD; Rojas-Calderón EL; Ocampo-García BE; Ferro-Flores G
    Appl Radiat Isot; 2015 Jun; 100():96-100. PubMed ID: 25305748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of two different types of LiF:Mg,Cu,P thermoluminescent dosimeters for detection of beta rays (beta-TLDs) from 90Sr/90Y, 85Kr and 147Pm sources.
    Grassi E; Sghedoni R; Piccagli V; Fioroni F; Borasi G; Iori M
    Health Phys; 2011 May; 100(5):515-22. PubMed ID: 21451322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hard beta and gamma emissions of 124I. Impact on occupational dose in PET/CT.
    Kemerink GJ; Franssen R; Visser MG; Urbach CJ; Halders SG; Frantzen MJ; Brans B; Teule GJ; Mottaghy FM
    Nuklearmedizin; 2011; 50(6):240-6. PubMed ID: 21876870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities.
    Breeman WA; De Jong M; Visser TJ; Erion JL; Krenning EP
    Eur J Nucl Med Mol Imaging; 2003 Jun; 30(6):917-20. PubMed ID: 12677301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduction of β-radiation exposure during preparation of 188Re-labelled Lipiodol for hepatocellular carcinoma treatment.
    Lepareur N; Laffont S; Ardisson V; Noiret N; Garin E
    Nucl Med Commun; 2012 Feb; 33(2):205-8. PubMed ID: 22124362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of organ absorbed doses and estimation of effective doses from pediatric anthropomorphic phantom measurements for multi-detector row CT with and without automatic exposure control.
    Brisse HJ; Robilliard M; Savignoni A; Pierrat N; Gaboriaud G; De Rycke Y; Neuenschwander S; Aubert B; Rosenwald JC
    Health Phys; 2009 Oct; 97(4):303-14. PubMed ID: 19741359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma.
    Forrer F; Riedweg I; Maecke HR; Mueller-Brand J
    Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):334-40. PubMed ID: 18480742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors.
    Frilling A; Weber F; Saner F; Bockisch A; Hofmann M; Mueller-Brand J; Broelsch CE
    Surgery; 2006 Dec; 140(6):968-76; discussion 976-7. PubMed ID: 17188146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
    J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single vial kit formulation of DOTATATE for preparation of (177) Lu-labeled therapeutic radiopharmaceutical at hospital radiopharmacy.
    Mukherjee A; Lohar S; Dash A; Sarma HD; Samuel G; Korde A
    J Labelled Comp Radiopharm; 2015 Apr; 58(4):166-72. PubMed ID: 25765604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.